ClinicalTrials.gg
CompletedNCT05743075Updated Jun 4, 2025

A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Phase 3 interventional study of Ensifentrine and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Nuance Pharma (shanghai) Co., Ltd. Completed at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Nuance Pharma (shanghai) Co., Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
526
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.

Enrollment
4th of 15
526 · median 79
Started
2023
with 1 other
Phase 3
5 of 15
1 open now
Registered
10th of 15
by date
Lead sponsor
2 of 15
Nuance Pharma (shanghai) Co., Ltd

Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 4th largest by enrollment, is one of 2 that started in 2023, is one of 5 in phase 3, and was the 10th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ensifentrine

ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical study, which aims to evaluate the efficacy, safety, and PK characteristics of Ensifentrine 3 mg twice daily (BID) for 24 weeks treatment of moderate to severe COPD.

Read the detailed description

The study is divided into 3 periods, a screening/run-in period (run-in for 28 days), a treatment period (24 weeks), and a follow-up period (1 week after the end-of-treatment visit). The qualified subjects will be randomly assigned to the Ensifentrine group or placebo group in a ratio of 5:3, stratified by maintenance therapy in a stable background long-acting muscarinic antagonist (LAMA) or long-acting β2 agonist (LABA) (yes or no) and smoking status (current or past smokers). The Ensifentrine group will receive Ensifentrine 3mg BID nebulizer, and the placebo group will receive placebo nebulizer. The treatment will be lasted given for 24 weeks in both groups.

During treatment, lung function, COPD symptoms, quality of life and other parameters of subjects will be assessed at baseline, week 6, 12, and 24, and the safety will also be assessed over 24-week treatment period and the follow-up period. PK characteristics and dose-response relationship of Ensifentrine will be analyzed for all patients using sparse sampling.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be 40 to 80 years of age inclusive, at the time of Screening, male or female;
  2. Current or former cigarette smokers with a history of cigarette smoking ≥ 10 pack-years;
  3. Patients with a clear clinical history of and related symptoms prior to screening;
  4. Patients with moderately to severe COPD:

    Pre- and Post- salbutamol /FVC ratio \< 0.70; and Post-salbutamol FEV1 ≥ 30% and ≤ 70% of predicted

  5. A score of ≥2 on the Modified Medical Research Council Dyspnea Scale at screening;
  6. Patients on no maintenance/background therapy or patients on stable maintenance as either LAMA or LABA therapy.
  7. Short-acting β2 agonists (SABAs) should be withheld for at least 6 hours prior to initiation of any spirometry;
  8. Female subjects of must have a negative blood pregnancy test 7 days prior to randomization and not be pregnant or lactating. Female subjects of childbearing potential and male subjects with partners of childbearing potential are required to use at least one effective method (such as intrauterine contraceptive device, contraceptives or condom) from the screening period, throughout the study period and for at least 30 days after the last dose of blinded product.

Exclusion criteria

Exclusion Criteria:

  1. History of life-threatening including Intensive Care Unit admission and/or requiring intubation;
  2. Hospitalizations for COPD, pneumonia, or Corona Virus Disease 2019 (COVID-19) in the 12 weeks prior to Screening and/or COPD exacerbation, Newly-occurring pneumonia, a positive COVID-19 test result indicating an active infection before Screening;
  3. Patients with lower respiratory tract infection occurred and not resolved within 6 weeks prior to screening and/or prior to randomization;
  4. COPD exacerbation requiring oral or parenteral (intravenous, subcutaneous, or intramuscular injection) within 3 months prior to screening;
  5. Previous lung resection, OR lung reduction surgery within 1 year of screening;
  6. Patients with long term of oxygen use;.
  7. Patients with pulmonary rehabilitation;
  8. Patients with other respiratory disorders including, but not limited to, current diagnosis of asthma, active tuberculosis, lung cancer, sarcoidosis, pulmonary fibrosis, interstitial lung disease, unstable sleep apnea, known alpha-1 antitrypsin deficiency, cor pulmonale, pulmonary hypertension, clinically significant bronchiectasis, or other active pulmonary disease;
  9. Major surgery (requiring general anesthesia) within 6 weeks prior to screening;
  10. Historical or current evidence of clinically significant cardiovascular disease defined as any disease that in the opinion of the Investigator would put the safety of the patient at risk through participation or which could affect the efficacy or safety analysis if the disease/condition were to exacerbate during the study.
  11. Chronic uncontrolled disease including, but not limited to, endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, psychiatric, or ophthalmic diseases that the investigator believes are clinically significant;
  12. Unstable liver disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones);
  13. History of within the past 5 years (except for cured basal cell carcinoma or squamous cell carcinoma of skin, cervical carcinoma in situ), or current potential malignancy under evaluation;
  14. Abnormal findings on physical examination that an investigator considers to be clinically significant at screening;
  15. Chest X-ray (CXR; posterior-anterior) at screening, or in the 12 months prior to screening with clinically significant abnormalities not attributable to COPD;
  16. (ECG) finding that is significantly abnormal at Screening;
  17. Abnormal lab test result, such as \< 30 mL/min, ≥ 2 × (ULN), alkaline phosphatase and/or > 1.5 × ULN, or any other abnormal hematology, biochemistry, or viral serology deemed by an investigator to be clinically significantly abnormal;
  18. Use of an experimental drug within 30 days or 5 half-lives prior to screening (whichever is longer), and/or participation in an interventional clinical trial within 30 days prior to screening;
  19. Use of an medical device or participation as a subject in a medical device clinical trial within 30 days prior to screening;
  20. Intolerance or to salbutamol or Ensifentrine (RPL554) or any of its /components;
  21. Use of traditional Chinese medicine within 2 weeks prior to first dose of Ensifentrine/ Placebo, which with antispasmodic and anti-asthmatic effects and interfering with respirometry test,that would interfere with the study based on the investigator's discretion;
  22. Any other reason that the Investigator considers makes the patient unsuitable to participate.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
526 participants (actual)

Study arms

  • Experimental
    Ensifentrine

    Eligible subjects will be randomly assigned in a 5:3 ratio to receive either Ensifentrine or placebo. Doses and methods of administration are as follows: Ensifentrine (RPL554) 3 mg BID or placebo BID will be administered by aerosol inhalation for 24 weeks; each nebulization time wil be approximately 5 minutes.

    Drug: Ensifentrine

  • Placebo comparator
    Placebo

    Eligible subjects will be randomly assigned in a 5:3 ratio to receive either Ensifentrine or placebo. Doses and methods of administration are as follows: Ensifentrine (RPL554) 3 mg BID or placebo BID will be administered by aerosol inhalation for 24 weeks; each nebulization time wil be approximately 5 minutes.

    Drug: Placebo

Interventions

  • A dual PDE3/PDE 4 inhibitor

  • DrugPlacebo

    Placebo solution

06

What researchers measure

Primary outcomes

  1. Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h

    Change from baseline of Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h

    Time frame: 12 weeks

Secondary outcomes

  1. Peak FEV1 over 4 hours post-dose at Week 12

    Change from baseline of Peak FEV1 over 4 hours post-dose at Week 12

    Time frame: 12 weeks

  2. Peak FEV1 at Week 6 and Week 24

    Change from baseline peak FEV1

    Time frame: 6 or 24 weeks

  3. Morning trough FEV1 at Week 6 and Week 24

    Change from baseline morning trough FEV1

    Time frame: 6 or 24 weeks

  4. Average FEV1 AUC0-4h at Week 6 and Week 24

    Change from baseline average FEV1 AUC0-4h

    Time frame: 6 or 24 weeks

  5. Average FEV1 AUC0-4h at Week 12

    Change from baseline average FEV1 AUC0-4h

    Time frame: 12 weeks

  6. Morning trough FEV1 at Week 12

    Change from baseline of morning trough FEV1 at Week 12

    Time frame: 12 weeks

  7. Evening trough FEV1 at Week 12

    Change from baseline of evening trough FEV1 at Week 12

    Time frame: 12 weeks

  8. Average FEV1 AUC6-12h at Week 12

    Change from baseline of Average FEV1 AUC6-12h at Week 12

    Time frame: 12 weeks

  9. Rescue medication use at Weeks 6, 12 and 24

    Change from baseline of Rescue medication use

    Time frame: 6, 12 or 24 weeks

  10. Evaluating-Respiratory Symptoms (E-RS) Total Score at Weeks 6, 12 and 24

    Change from baseline of Evaluating-Respiratory Symptoms (E-RS) Total Score

    Time frame: 6, 12 or 24 weeks

  11. SGRQ total score at Weeks 6, 12 and 24

    Change from baseline of SGRQ total score

    Time frame: 6, 12 or 24 weeks

  12. SGRQ responder analysis at Weeks 6, 12 and 24

    Change from baseline of SGRQ responder analysis

    Time frame: 6, 12 or 24 weeks

  13. TDI total score at Weeks 6, 12 and 24

    Change from baseline of TDI total score

    Time frame: 6, 12 or 24 weeks

  14. CAT total score at Weeks 6, 12 and 24

    Change from baseline of CAT total score

    Time frame: 6, 12 or 24 weeks

07

Study locations

1 site
  • 1st Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Dec 2024, 20 months.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 20 months is close to that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2023
First posted
Feb 24, 2023
StartActual
Mar 10, 2023
Primary completionActual
Dec 6, 2024
CompletionActual
Mar 7, 2025
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05743075
Lead sponsor
Nuance Pharma (shanghai) Co., Ltd
Collaborators
Laboratory Corporation of America
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Mar 10, 2023
Primary completion
Dec 6, 2024
Completion
Mar 7, 2025
Last update
Jun 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensifentrine

Start the discussion